ANTWERPEN, BELGIUM, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - This marks the 11th time the company has been recognized as a Leader. OMP believes this recognition underscores its consistent delivery of innovative solutions such as UnisonIQ and Unison Decision-Centric Planning. It reflects a market shift toward AI-driven supply chain planning, and the growing demand for platforms that unify strategy, execution, and intelligence in real time.Advancing intelligent planning for the most complex supply chain needsTrusted by Fortune 500 leaders such as AstraZeneca, BASF, Johnson & Johnson, and Procter & Gamble, OMP continues to advance supply chain planning through Unison Planning™, its proven end-to-end platform. Open, cloud-native, and AI-driven, the platform is built to meet the evolving demands of process and discrete global supply chains, including chemicals, consumer goods, life sciences, paper and packaging, tires and building products, and metals.Unison Planning™ incorporates UnisonIQ, OMP's AI orchestrator that unifies AI agents, assistants, and engines into one powerful framework. Designed for the agentic age of supply chain planning, UnisonIQ embeds continuous intelligence throughout the platform, giving organizations a foundation for proactive, autonomous decision-making grounded in deep industry expertise."Agentic AI is fundamentally reshaping how supply chains operate and compete," says Paul Vanvuchelen, Chief Executive Officer at OMP. "Organizations that embrace this shift will turn volatility into strategic advantage."Accelerating decision velocity for the entire supply chainOMP's Unison Decision‑Centric Planning elevates supply chain performance by uniting human expertise, advanced AI, real‑time intelligence, and rapid scenario evaluation to drive decision velocity and improve decision quality across the enterprise."With comprehensive supply chain intelligence and AI-powered anticipation, Unison Decision-Centric Planning enables organizations to gain earlier visibility into disruption, evaluate its impact, and prepare the next move with clarity and confidence," says Philip Vervloesem, Chief Commercial & Markets Officer at OMP.About the Gartner Magic QuadrantThe 2026 Gartner Magic Quadrant for Supply Chain Planning Solutions: Process Industries, released in March 2026, evaluates vendors based on their Ability to Execute and Completeness of Vision, helping global companies identify the right partners in a complex and fast-evolving market.We believe this recognition comes alongside OMP's strong performance in the 2026 Gartner Critical Capabilities for Supply Chain Planning Solutions Process Industries report, where it had been ranked in the highest two positions across all Use Cases. OMP also continues to receive strong customer ratings on Gartner Peer Insights™, reflecting positive feedback from enterprise users.For more information about OMP's position as a Leader in the Gartner Magic Quadrant and the future of supply chain planning, read the full report.Meet OMP at the Gartner Supply Chain Symposium/Xpo™OMP will participate in the 2026 Gartner Supply Chain Symposium/Xpo™, where customers will share practical insights on intelligent, decision-centric supply chains:Procter & Gamble will present key learnings from its collaboration with OMP at the Symposium/Xpo™ US, highlighting how integrated planning and end-to-end visibility drive measurable business impact.AstraZeneca will present its journey toward decision-centric autonomous planning at the Symposium/Xpo™ EMEA, highlighting how it is transforming processes and capabilities to achieve excellence.About OMPOMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, plastics & packaging, tires and building products - benefit from using OMP's unique Unison Planning™.Gartner, Magic Quadrant for Supply Chain Planning Solutions, Pia Orup Lund, Joe Graham, Buse Aras, Jan Snoeckx, Eva Dawkins, Julia von Massow, 18 March 2026.Gartner, Critical Capabilities for Supply Chain Planning Solutions: Process Industries, Julia von Massow, Eva Dawkins, Jan Snoeckx, Buse Aras, Joe Graham, Pia Orup Lund, 18 March 2026.Gartner and Magic Quadrant are trademarks of Gartner, Inc., and/or its affiliates.Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.Solution and product inquiriesContact OMPMedia inquiriesKira Perdue (Carabiner)SOURCE: OMP Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TAMPA, FLA., Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.About Wellgistics Health, IncWellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.About Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-incForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Key Results Highlights:- Revenue Growth: 8.6% increase to approximately HK$1,813.8 million- Net Profit Increase: 3.5% rise to HK$318.1 million, driven by operational efficiency- Final Dividend: Proposed final dividend of HK7.0 cents per share, bringing total dividend for 2025 to HK14.0 cents per share, a 16.7% surge from HK12.0 cents in 2024- Net Cash & Cash Equivalents: HK$782.7 million (HK$557.2 million as at 31st December 2024)Regulatory Milestones:- NMPA Approval: Multi-dose Diquafosol Sodium Eye Drops approved in July 2025; multi-dose Sodium Hyaluronate Eye Drops approved in January 2026 for registration and commercialisation in the PRC- BLA Acceptance: Bevacizumab ophthalmic injection BLA accepted by NMPA in August 2025, marking a crucial regulatory milestoneBusiness Developments:- Exclusive Distribution (Seefunge): Exclusive distribution of Seefunge's Emedastine Difumarate and Oxybuprocaine Hydrochloride Eye Drops in the PRC- Exclusive Distribution (Osteopore): Exclusive distribution of Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau.- Collaboration with Airdoc: Joint operation of Artificial Intelligence-based retinal businesses in the PRC- Strategic Collaboration with Kenvue: Promotion and marketing of Kenvue's consumer health products (Rhinocort(R), Motrin(R), Tylenol(R)) in the PRC.- International Innovation Accelerator: Signed MOU with Suzhou Industrial Park to launch cross-border life sciences accelerator.- First Overseas Market Entry: Beifushu(R) introduced to Singapore via Special Access Route at Singapore National Eye Centre.Intellectual Property and Market Presence:- Robust IP Portfolio: 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.- Extensive Distribution Network: Products available in over 14,600 hospitals and medical providers, and approximately 2,600 pharmaceutical stores across the PRCAwards and Recognition:- 2025 Top 500 Manufacturing Companies in Guangdong Province: Recognises industrial scale and comprehensive competitiveness- National Manufacturing Champion Enterprise: Affirms leading position in specialized biopharmaceutical segment- 2025 "Golden Kunpeng" China Financial Value Ranking – Most Valuable Listed Company for Investment: Highlights capital market recognition of growth potential- Participation at Asia-Pacific Academy of Ophthalmology Congress 2026: Showcasing key ophthalmology products and pipeline assets, strengthening engagement with regional eye care professionals and institutions.HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” and its subsidiary the “Group”, Stock Code: 1061.HK), a leading biologic Group that develops, manufactures and commercialises genetically engineered therapeutic recombinant bovine basic fibroblast growth factor (“rb-bFGF”), today announced robust annual results for the year ended 31st December 2025, with revenue up 8.6% to HK$ 1,813.8 million and net profit up 3.5% YoY to HK$318.1 million. The Group achieved multiple regulatory milestones and expanded its product portfolio through strategic collaborations, and Beifushu’s landmark entry into Singapore. These achievements underscore Essex's commitment to innovation and operational excellence, driving sustained revenue and profit growth.Diversified Growth Fueled by Flagship BiologicsThe Group achieved a consolidated turnover of approximately HK$1,813.8 million, with an increase of 8.6% as compared to approximately HK$1,669.8 million in 2024. Correspondingly, the Group’s profit increased by 3.5% to approximately HK$318.1 million as compared to approximately HK$307.2 million in 2024.The Beifushu(R) series and Beifuji(R) series, the Group’s flagship products drove growth, contributing 83.5% of turnover.The ophthalmology segment (“Ophthalmology”) recorded a turnover of HK$835.0 million, grew 8.2% year-on-year, led by Beifushu(R) unit-dose eye drops and supported by its preservative free design and expanding application scenarios, which cover multiple areas such as dry eye treatment and post-operative recovery, and contributions from Beifushu(R) eye gel, (Iodized Lecithin Capsules) and a range of unit-dose eye drops (Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops).The surgical segment (“Surgical”) turnover rose 1.8% year-on-year to HK$895.9 million, leveraging Beifuji’s broad clinical applications across multiple medical departments and strong market presence. It is also supported by numerous clinical guidelines and expert consensus, thereby laying a solid foundation for future indication expansion and sustained growth. In addition, Group Carisolv(R) dental caries removal gel, PELNACTM collagen-based artificial dermis and SCALGENTM double-layered artificial dermis had further strengthened and contributed to the Surgical business.Notably, Healthcare and Partner Services delivered a total turnover of approximately HK$82.9 million for the year ended 31st December 2025, representing a significant increase of 350% as compared to 2024. The growth was primarily driven by Dr. YaDian oral care products, online and offline healthcare services and CMO/CDMO services.Strengthening Financial Position and Shareholder ReturnsThe Group maintains a healthy financial position, with cash and cash equivalents of approximately HK$782.7 million as of 31st December 2025. Bank borrowings stand at HK$325.6 million, with a manageable repayment schedule over 5 years period. The Group’s gearing ratio is at 30.9% (2024: 28.8%), indicating disciplined financial management and ample liquidity.The Board is pleased to propose a final dividend of HK7.0 cents per ordinary share. Together with the interim dividend of HK7.0 cents per ordinary share, the total dividend for 2025 reaches HK14.0 cents, representing a notable year-on-year increase of 16.7% from HK12.0 cents in 2024, demonstrating the Group’s ongoing commitment to delivering greater returns to its shareholders.Broad Portfolio and Robust Pipeline Fuel Sustained GrowthThe Group’s business comprises three core segments: Ophthalmology, Surgical (wound care and healing) and Healthcare and Partner Services segment, with the Group’s six (6) flagship commercialised biologics, collectively referred to as the “bFGF Series”, which are marketed and sold in the PRC. Three of the bFGF Series were approved by NMPA as Category I drugs, and five are listed on the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance in the PRC.In addition, the Group offers a portfolio of commercialised preservative-free unit-dose eye drops, including Tobramycin, Levofloxacin, Sodium Hyaluronate, Moxifloxacin Hydrochloride and Diquafosol Sodium Eye Drops. The Group further expanded its ophthalmology franchise by obtaining NMPA approvals for the registration and commercialisation of multi-dose Diquafosol Sodium Eye Drops in July 2025 and multi-dose Sodium Hyaluronate Eye Drops in January 2026. The new launches target the PRC’s growing dry eye treatment market, complementing the Group’s Beifushu(R) ophthalmic repair series.As for the Surgical segment, the Group’s Carisolv(R) dental caries removal gel, Portable Ultraviolet Phototherapy Devices, PELNACTM collagen-based artificial dermis, SCALGENTM double-layered artificial dermis and Osteopore’s bioresorbable implants (Osteomesh(R) and Osteoplug(R)), are complementing the Group’s Beifuji(R) wound healing series.Strategic R&D Investment to Capture Emerging Market OpportunitiesThe Group is committed to pragmatically investing in new products and technologies to strengthen its product and R&D pipeline, with a mission to develop groundbreaking therapeutics that address unmet clinical and commercial needs. In 2025, total R&D expenditures were approximately HK$177.2 million, representing 9.8% of the turnover, of which approximately HK$139.3 million were capitalised.During the year, the Group’s Medical Scar Repair Gel obtained NMPA registration approval as a Class II medical device, expanding the Group’s footprint in the fast-growing high-end wound care and medical aesthetics markets, unlocking new growth drivers for long-term success.The global phase 3 clinical project of bevacizumab ophthalmic injection (EB12-20145P) has successfully completed patient enrolment across the PRC, Australia, European Union countries and the United States, with the last patient last visit was completed. A Biologics License Application (BLA) was accepted by NMPA in the PRC in August 2025.To amplify the Group’s presence in the Asia ophthalmic community and accelerate the market launch of new products, the Group participated in the 2026 Asia-Pacific Academy of Ophthalmology (APAO) Congress. The event provided a premium platform to showcase ophthalmic solutions, engage with regional clinical experts and partners, and build momentum for the rollout of its innovative ophthalmic products, reinforcing its global brand influence.The Group holds a total of 121 patent certificates or authorisation letters, comprising 91 invention patents, 15 utility model patents and 15 design patents.The Group currently has multiple R&D sites located in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore. These sites support the Group’s efforts to develop new therapeutics and recruit global talent.To date, the Group has 18 R&D programmes ranging from pre-clinical to clinical stages, with several ophthalmology programs currently in the clinical stage, specifically Bevacizumab intravitreal injection, SkQ1 eye drops and Cyclosporine eye dropsBroadening Commercial Reach Through Market Expansion and PartnershipsAs of 31st December 2025, the Group maintains an extensive network of 47 regional sales offices in the PRC and a strategic base in Singapore to facilitate market access into Southeast Asian countries. With a vast distribution network, the Group’s products are prescribed in more than 14,600 hospitals and medical providers, coupled with approximately 2,600 pharmaceutical stores, covering major cities throughout the PRC.During the year under review, the Group achieved multiple landmark breakthroughs in the PRC and overseas market expansion, unlocking new multi-dimensional growth momentum. In the overseas market, the Group’s flagship product Beifushu(R) was successfully introduced to Singapore via the Special Access Route at the Singapore National Eye Centre, marking the product’s first commercial launch beyond the PRC, and establishing a solid foothold to support the Group’s future expansion into Southeast Asia and global markets.In the PRC market, the Group entered into two landmark strategic partnerships during the year: a collaboration with global consumer health leader Kenvue, under which the Group will leverage its extensive nationwide commercial network in the PRC to carry out promotion, medical education and marketing for Kenvue’s selected consumer health products including Rhinocort(R) (Budesonide Nasal Spray), Motrin(R) (Ibuprofen Suspension/Drops), and Tylenol(R) (Paracetamol Drops/Suspension); and an exclusive distribution agreement for Osteopore’s innovative dental, orthodontic and maxillofacial products in the PRC, Hong Kong and Macau, marking a strategic entry into the high-potential stomatology market. The partnerships broaden the Group’s healthcare business footprint, delivering strong synergies with its existing ophthalmology and regenerative medicine lines.To drive sustainable growth and expansion for its current and future products, the Group has been investing relentlessly in enhancing its competitiveness and broadening its reach by expanding the clinical indications for its commercialised products, increasing patient access in lower-tier cities across the PRC, developing complementary sales channels, and nurturing the healthtech e-platform to enhance patient access.The Group’s second factory at Zhuhai Hi-Tech Industrial Park, with a gross floor area of about 58,000 square meters for R&D, manufacturing, office and dormitory, is expected to complete in the period of 2026 -2027.Mr. Patrick Ngiam, Chairman of Essex, said “2025 was a standout year with Beifushu’s landmark entry into Singapore, driving robust growth through flagship products, innovation-focused R&D, and strategic partnerships. Essex remains committed to addressing unmet needs and driving long-term growth.We will proactively and systematically recalibrate operating and distribution costs to mitigate the negative impact on FY26 profit from the increase of VAT from 3% to 13% without disrupting our focus on Group development plans.”About EssexBio (1061.HK)EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,600 hospitals, supported by the Company’s 47 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Brisbane, Australia--(ACN Newswire via SeaPRwire.com - March 23, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has officially launched its European sales activity. During the week of March 9th, GMG held a kick off training workshop in London where it brought together its new team members from various locations in Europe and UK for technical product and sales training.The GMG European Sales team numbers more than 10 professional sales executives based in Europe and UK who focus on lead generation, inside sales and executive sales business development for GMG's G® Lubricant and THERMAL-XR® products.Figure 1: Members of the GMG European Sales TeamTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/289529_gmg_figure1.jpgSeparately, the Company is also pleased to announce that it has been informed that the G® Lubricant patent in Europe has been accepted to be granted for a period of 20 years.Craig Nicol, CEO & Managing Director of the Company, commented "Building a sales force in key areas of the world is one of GMG's key activities it is focused on right now and to get the European team set up and running so fast has been a great achievement."Jack Perkowski, Chairman and Non-Executive Director of the Company, commented: "I congratulate the Company on building the European Sales team and look forward to hearing of future success."About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the size, term and success of GMG's European sales team and the eventual granting of and successful enforceability of the Company's G® Lubricant patent.Such forward-looking statements are based on a number of assumptions of management, including the European sales team will perform and the Company's G® Lubricant patent will be patented successfully. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that the GMG European Sales team does not successfully drive sales for the Company and the Company's G® Lubricant patent is not patented and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289529 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
SINGAPORE, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - Travelling overseas is exciting, but foreign exchange (FX) fees can quietly add up and increase your overall trip expenses. Many Singaporeans are now exploring smarter ways to manage overseas spending, and a multi-currency debit card can help reduce unnecessary FX charges while shopping, dining, and booking activities abroad. Whether you are heading to Japan, Australia, Europe, or the US, understanding how FX fees work can help you stretch your Singapore dollars further. Even a 3% fee on a SGD 5,000 trip translates to SGD 150, which could easily cover a nice meal or attraction tickets.When spending overseas, banks typically apply a currency conversion spread and may also charge overseas transaction fees ranging between 2.5% and 3.5%. On top of that, dynamic currency conversion at merchants can add another 4-8% markup. These layered charges might not be obvious at checkout, but they can significantly increase your travel budget.With a bit of planning and the right payment tools, Singaporeans can minimise these costs and enjoy more transparent spending abroad.Understanding Where FX Fees Come FromBefore looking at solutions, it helps to understand how FX fees are structured. Most traditional credit and debit cards issued in Singapore apply a foreign transaction fee when you pay in a currency other than SGD. This fee usually combines the card network's conversion rate and an additional bank administrative charge.For example, if you spend the equivalent of SGD 1,000 in Bangkok or Seoul, a 3% fee adds around SGD 30 to your statement. Over a 10-day trip with shopping and dining expenses of SGD 4,000, total FX charges could reach SGD 120 or more. These amounts may seem small per transaction but can accumulate quickly across hotels, theme parks, transport passes, and shopping malls.How a Multi-Currency Debit Card Can HelpA multi-currency debit card allows users to hold and spend multiple foreign currencies directly from one account. Instead of converting SGD at the point of sale for every purchase, you can preload currencies such as USD, EUR, JPY, or AUD in advance. This setup can help reduce conversion fees and give you more control over exchange rates.For instance, if you are travelling to Japan and expect to spend the equivalent of SGD 3,000, you can convert SGD to JPY when rates are favourable before departure. If the exchange rate improves even by 1%, that difference could mean savings of around SGD 30 on your total spend.Many multi-currency debit cards also offer competitive interbank or near-interbank rates with low or zero foreign transaction fees. While terms vary by provider, this structure may result in lower overall costs compared to traditional cards. Additionally, you can track balances in different currencies via mobile apps, which helps you manage budgets more clearly during travel.Practical Ways Singaporeans Can Reduce FX ChargesBeyond choosing the right card, several practical habits can help minimise FX fees while shopping overseas.Pay in the local currency whenever possibleWhen a payment terminal offers the option to pay in SGD or the local currency, selecting the local currency can help you avoid dynamic currency conversion markups. Merchants may apply rates that are 4-8% higher than market rates when you choose SGD. On a SGD 2,000 shopping bill in Seoul, that difference could translate to an extra SGD 80 or more. Paying in the local currency often results in a more transparent rate from your bank or card provider.Plan large purchases in advanceIf you are considering buying luxury goods in Europe or electronics in Japan, estimating your total spend beforehand can help you prepare accordingly. Planning major purchases can also help you avoid last-minute conversions at less competitive airport rates.Avoid exchanging large sums at airportsAirport money changers often offer less competitive exchange rates compared to city money changers in Singapore or digital FX platforms. The difference might range from 1% to 3%. On SGD 2,000 exchanged at the airport, this gap could mean paying SGD 20 to SGD 60 more than necessary. Using a multi-currency debit card for most transactions can reduce the need to carry large amounts of cash.Monitor overseas ATM withdrawal feesWithdrawing cash overseas may involve both local ATM fees and your bank's overseas withdrawal charges. These combined costs can range between SGD 5 and SGD 15 per withdrawal, excluding FX spreads. Planning fewer, slightly larger withdrawals, or relying more on card payments, can help reduce repeated charges. Some multi-currency debit cards may offer more competitive ATM withdrawal terms, depending on the provider.Comparing Travel Spending OptionsCredit cards may offer travel rewards but often carry foreign transaction fees of around 3%. Using cash helps you to do away with card fees but requires you to exchange money upfront, sometimes at less competitive rates.A multi-currency debit card sits somewhere in between, combining digital convenience with potentially lower FX costs, while offering more flexibility. For frequent travellers visiting destinations like Malaysia, Thailand, Japan, Australia, or the US several times a year, this flexibility can make budgeting more predictable.Avoiding FX fees does not require complex strategies. Small adjustments in how you pay, when you convert currency, and which card you use can collectively reduce costs. While exchange rates fluctuate and fees vary across providers, informed decisions can help you minimise hidden charges and make the best of your overseas trips.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 2026年3月20日，专注于中国内地投资及优质资产持有运营的中国新城镇发展有限公司（"中国新城镇"或"公司"，及其附属公司，统称"集团"；香港股票代号：01278.HK）欣然宣布截至2025年12月31日止12个月（"2025年"或"回顾期"）之经营业绩。回顾期内，集团持续深化改革转型路径，在攻坚克难中交出高质量答卷。2025年集团录得主营业收入约3.89亿元（单位：人民币，下同），同比增长15%；年内溢利7571万元，同比增长35.5%；母公司权益拥有人应占溢利总额约7329万元，同比增长65.4%。董事会建议派发末期股息为每股普通股0.0025港元。主营业务稳健增长，固收业务持续优化回顾期内，集团继续保持稳健经营。2025年公司实现城镇化投资收入2.31亿元，同比增长约25%，主要因为城镇化项目投资余额较去年同期增加，对应项目投资收入增加。实现物业租赁及管理费收入人民币约1.00亿元，包括物业租赁收入人民币0.76亿元、物业管理费收入人民币0.24亿元。实现工程建设收入人民币5,717.5万元。面对国内外复杂经济形势，集团依托股东无锡交通集团与国开金融的资源优势，充分发挥"地方国资+央企金融机构"的业务网络效应，做好主营业务的管理及运营，实现了稳定增长。2025年集团城镇化投资业务稳中有进，持续贡献稳定现金流。截至2025年12月31日，固定收益投资组合总额达人民币33.66亿元。优质资产运营稳中提质。武汉光谷物业项目面对市场压力实现"止跌回升"，通过精准招商与服务升级，年底平均出租率回升至75%，保证了投资性房地产估值的稳定。借力股东资源聚焦战略转型，拓展增长新空间2025年集团紧抓国家大力发展新质生产力的政策机遇，结合股东的资源优势，围绕集成电路、新能源、新材料、高端装备制造、环保等新经济方向进行优质股权项目储备，战略并购路径逐步聚焦及清晰，拟通过持有不同行业的优质资产，打造稳健收入及现金流以及后续新业务领域的增长空间。值得一提的是，集团发挥股东协同优势，在实现经营业绩稳健增长的同时，融资工作取得重大突破，成功发行15亿元离岸人民币债券，用于现有债务的再融资，进一步降低了债务成本并优化了期限结构，为集团后续业务的发展提供可持续的资金支援。持续派息，提供稳定股东回报2025年集团拟派发末期股息0.0025港币/股，加上中期已经派发的中期股息0.0016港币/股，2025年集团全年派息金额约3900万港元。自2023年中期恢复派息以来，集团累计已经派发及拟派发股息金额达到了约1.2亿元人民币，显示了持续回报股东的意愿和行动。未来展望展望2026年，作为"十五五"开局之年，集团将紧扣国家新质生产力导向，聚焦战略新兴产业与信创产业，加速业务转型。固收业务稳中提质，保障现金流；优化武汉光谷等核心资产运营，提升效能。同时，积极储备优质股权项目，力争战略并购实质突破，持续为股东创造核心价值。关于中国新城镇发展有限公司中国新城镇（香港联交所股份代号︰1278）为中国内地的投资及优质资产运营商。自2014年起，本集团顺应中国新城镇化发展趋势优化了业务模式，以"投资+下游产品运营"的业务模式，通过固定收益类项目投资作为出发点，持有优质资产管理及运营，同时以市场为导向，全力在新材料、半导体、高端装备制造等新经济领域拓展股权投资业务，积累行业投资经验。本新闻稿由千里国际顾问有限公司代表中国新城镇发展有限公司发布。如有垂询，请联络：中国新城镇发展有限公司 ir@china-newtown.com千里国际顾问有限公司Fancy Wang fancywang@maxima.hk Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年3月23日 - (亚太商讯 via SeaPRwire.com) - 人形机器人赛道再迎里程碑事件。3月20日，上交所官网显示，宇树科技股份有限公司科创板IPO申请已获受理，融资金额42.02亿元，审核状态为"已受理"。这意味着宇树科技正式向"A股人形机器人第一股"发起冲刺，也标志着具身智能产业开始从主题催化迈向资本化兑现的新阶段。从公开披露看，宇树科技此次IPO并非单纯的概念升温，而是建立在业绩高增长与产能扩张预期之上。根据公司招股说明书透露，公司2025年实现营业收入17.08亿元，同比增长335.36%；扣非后净利润超过6亿元，同比增长674.29%；公开发行新股不低于4044.64万股，占发行后总股本比例不低于10%。对资本市场而言，宇树科技最重要的意义，是开始提供一个更清晰的人形机器人估值参照系。公开报道显示，宇树科技在2025年初的估值约为50亿元，到2025年6月已提升至约120亿元；而本次招股书对应的初始发行后市值至少420亿元，意味着其公开市场估值门槛较2025年中期的一级市场口径又出现大幅跃升。对于资本市场而言，宇树科技的上市进程则是释放出一个清晰信号：人形机器人不再只是"技术想象力"的故事，而开始进入"收入、利润、产能、融资"四线并进的新阶段。对产业链而言，这将提升市场对整条赛道估值锚的清晰度；对已提前布局头部机器人的资本平台而言，则意味着账面价值、退出预期与业务协同空间都有望同步抬升。在这一轮受益标的中，首程控股（0697.HK）的稀缺性尤为突出。公司在官方披露中明确表示，已通过北京机器人产业发展投资基金及旗下产业基金，投资宇树科技、银河通用、星海图、松延动力等多家头部企业；到2025年前三季度，其管理的多支产业基金又进一步完成了对宇树科技、云深处、加速进化、微分智飞、泉智博等核心机器人产业链公司的投资，覆盖人形机器人、飞行机器人及上游关键环节。换言之，首程控股并非单点押注，而是在"头部本体企业+上游关键环节+区域基金网络"上形成了组合式布局。更关键的是，首程控股的优势不只在"投"，还在"投后赋能"。公司2025年中报和三季报均提到，其正围绕"资金+场景+产业链"推进"投资+运营+生态"一体化路径，并已设立北京首程机器人科技产业有限公司、首程机器人先进材料产业有限公司，拓展销售代理、租赁、咨询、供应链管理及上游材料延伸。同时，公司在首钢园、北京首都国际机场T3、成都春熙路等场景布局常态化机器人体验店和快闪店，推动机器人产品从展示走向商业落地。对于宇树科技这类具备量产能力的明星企业而言，这种场景资源意味着更低的试错成本和更快的商业验证速度。这也是首程控股被市场视为宇树概念股的核心原因：它不是单纯二级市场"映射"，而是兼具资本纽带、应用场景和产业服务能力的生态型平台。一旦宇树科技IPO顺利推进，首先受益的是首程控股机器人投资组合的市场认可度。头部项目登陆资本市场后，外部投资者会更容易对首程控股存量未上市机器人资产进行对标估值。市场人士分析，从估值逻辑上看，宇树科技IPO对首程控股至少构成三重利好。其一，首程控股的投资收益兑现预期抬升。首程控股通过北京机器人产业基金持有宇树科技3.8262%股份，位列发行前前十大股东之一。考虑新股发行稀释后，这部分旧股对应的发行后持股比例约为3.44%。按420亿元发行后市值假设测算，这一部分股权价值约为14.46亿元；若对应500亿元、600亿元上市后市值，则股权价值约分别为17.22亿元和20.66亿元，这对比首程控股的净资产体量，具有显著的边际贡献，并将对首程控股现有估值体系形成边际支撑。其二，是平台型估值中枢提升。首程控股并非传统意义上的单一财务投资者。公司主业一方面是基础设施资产业务，另一方面是以基金和产业平台切入机器人、智能制造等新赛道。机器人赛道的公开市场估值锚形成后，首程控股整个机器人投资组合有望被整体重估。其三，是机器人生态商业化提速带来的第二成长曲线。过去市场给机器人概念股估值，往往停留在"参股收益"层面；但首程控股正在尝试把机器人变成真实运营业务。公司披露已在线下体验店、机场场景、文旅园区和智能停车等多个场景推进机器人落地，并与产业方合作推动"机器人+汽车"等新业态。若宇树科技IPO后品牌效应和融资能力进一步增强，首程控股有望从"投中受益"扩展到"运营分成、渠道服务、场景服务、供应链协同"的多元受益。届时，市场看待首程控股的框架，将会从"宇树概念股"升级为"机器人生态基础设施平台"。此外，首程控股的财务结构也为估值修复提供了安全边际。公司2024年归母溢利为4.10亿港元，2024年末本公司拥有人应占股本及储备为94.21亿港元，负债资本比率从2024年末的15.9%下降至2025年三季度的10.9%。公司就2024年度合共宣派末期股息及特别派息8.88亿港元，叠加中期股息2.08亿港元，全年派息总额10.96亿港元，超出当年归母溢利的200%。较强的分红意愿、较低杠杆与持续盈利能力，使其在"成长+收益"两端都更容易获得资金青睐。总体来看，宇树科技IPO正式推上进程，是2026年具身智能产业最重要的资本事件之一。它不仅提高了头部机器人企业的资本化确定性，也为首程控股这样的生态型平台打开了价值重估窗口。随着"明星项目上市—投资收益兑现—产业场景扩容—平台估值提升"逻辑逐步展开，首程控股有望成为本轮机器人行情中兼具安全边际与弹性的核心受益者之一。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) -The humanoid robotics sector has reached another milestone. On 20 March, the Shanghai Stock Exchange confirmed that Unitree Robotics Co., Ltd. (operating entity: Hangzhou Yushu Technology Co., Ltd.) has received formal acceptance of its STAR Market IPO application, targeting proceeds of RMB 4.202 billion, with review status recorded as "Accepted". This marks Unitree Robotics' official push to become China's first A-share listed humanoid robot company, and signals that the embodied-intelligence industry is transitioning from a theme-driven narrative phase into a new stage of genuine capital-markets realisation.From publicly disclosed information, this IPO is not purely a concept re-rating event — it rests on a foundation of strong earnings growth and capacity expansion. According to the company's prospectus, Unitree Robotics generated revenue of RMB 1.708 billion in 2025, up 335.36% year-on-year; non-GAAP net profit exceeded RMB 600 million, up 674.29% year-on-year. The public offering involves a minimum of 40,446,434 new shares, representing at least 10% of the total post-IPO share count.For the capital markets, the most important contribution of Unitree Robotics is that it begins to provide a clearer public-market valuation reference for the humanoid-robotics sector. Reports indicate that Unitree's valuation stood at approximately RMB 5 billion in early 2025, rising to approximately RMB 12 billion by June 2025. The prospectus implies an initial post-IPO market capitalisation of at least RMB 42 billion — a dramatic leap from the mid-2025 private-market benchmark. For the capital markets, Unitree's listing trajectory carries a clear signal: humanoid robotics is no longer purely a story of "technological imagination" — it is entering a new phase of revenue, profit, capacity, and capital advancing on all four fronts simultaneously. For the supply chain, this raises the clarity of the sector's valuation anchor; for capital platforms that have invested early in leading robotics companies, it means book values, exit expectations, and business synergies all have room to rise in tandem.Among the beneficiary candidates in this cycle, Shoucheng Holdings Limited (HKEX: 0697.HK) stands out for its rarity value. The company has publicly confirmed that, through the Beijing Robotics Industry Development Investment Fund and its affiliated sub-funds, it has invested in Unitree Robotics, Galbot (Beijing Galaxy General Robot Co., Ltd.; X Square Robot , Noetix Robotics, and other leading enterprises. By Q3 2025, the multiple funds it manages had further completed investments in Unitree Robotics, DEEP Robotics / Hangzhou DEEP Robotics Co., Ltd.), Booster Robotics, Differential Robotics / Differential Robotics Technology Inc.), Wuxi Quanzhibo Technology Co., Ltd., and other core robotics supply-chain companies — covering humanoid robots, aerial robots, and critical upstream components. In short, Shoucheng Holdings is not a single-bet position, but a portfolio-style deployment spanning "leading robot OEMs + upstream critical components + regional fund networks."Crucially, Shoucheng Holdings' edge lies not only in "investing" but also in "post-investment value creation." Both the company's 2025 interim report and Q3 report highlight that it is advancing an integrated "Invest + Operate + Ecosystem" pathway centred on "capital + scenarios + supply chain." It has established Shoucheng Robot Technology Industry Co., Ltd. and Shoucheng Robot Advanced Materials Industry Co., Ltd., expanding into sales agency, leasing, consultancy, supply-chain management, and upstream materials. Simultaneously, the company has deployed permanent robot experience stores and pop-up stores at Shougang Park, Beijing Capital International Airport Terminal 3, and Chengdu Chunxi Road, accelerating the transition of robot products from showcase to commercial deployment. For high-volume producers like Unitree Robotics, these venue resources translate into lower trial-and-error costs and faster commercial validation cycles.This is also the core reason why the market treats Shoucheng Holdings as a premier Unitree Robotics proxy: it is not a simple secondary-market "reflection" play, but an ecosystem-type platform that combines capital linkages, application venues, and industrial service capabilities. Once Unitree Robotics' IPO advances smoothly, the first beneficiary will be the market recognition of Shoucheng Holdings' existing robotics investment portfolio. With a marquee portfolio company achieving public listing, external investors will find it far easier to mark-to-market the unlisted robotics assets still held by Shoucheng Holdings.Market analysts observe that, from a valuation standpoint, the Unitree Robotics IPO represents at least three distinct positive catalysts for Shoucheng Holdings.First, the anticipated realisation of investment returns has been significantly enhanced. Shoucheng Holdings holds 3.8262% of Unitree Robotics through the Beijing Robotics Industry Development Investment Fund, placing it among the top ten pre-IPO shareholders. After accounting for dilution from the new share issuance, the post-IPO stake corresponds to approximately 3.44%. Based on an assumed post-IPO market capitalisation of RMB 42 billion, this stake implies a value of approximately RMB 1.446 billion; at market caps of RMB 50 billion and RMB 60 billion, the implied values are approximately RMB 1.722 billion and RMB 2.066 billion respectively. Against the scale of Shoucheng Holdings' net asset base, these figures represent a material incremental contribution and will provide meaningful support to the company's existing valuation framework.Second, the platform-level valuation midpoint has scope to re-rate upward. Shoucheng Holdings is not a traditional single-strategy financial investor. Its core business encompasses infrastructure asset operations on one side, and entry into robotics and intelligent manufacturing through funds and an industrial platform on the other. Once the robotics sector has an established public-market valuation anchor, Shoucheng Holdings' entire robotics investment portfolio stands to be re-valued in aggregate.Third, the acceleration of robotics ecosystem commercialisation opens a genuine second growth curve. In the past, the market valued robotics concept stocks largely at the level of "equity participation income." But Shoucheng Holdings is actively working to transform robotics into a real operating business. The company has disclosed that it is advancing robot deployment across multiple scenarios — offline experience stores, airport environments, cultural-tourism parks, and smart car parks — and is collaborating with industry partners to develop new business formats such as "robotics + automotive." Should Unitree Robotics' brand recognition and fundraising capacity strengthen further post-IPO, Shoucheng Holdings could expand beyond "investment gains" to capture diversified value streams including operating profit-sharing, channel services, scenario services, and supply-chain coordination. At that point, the market's analytical framework for Shoucheng Holdings would graduate from "Unitree Robotics proxy" to "robotics ecosystem infrastructure platform."In addition, Shoucheng Holdings' financial structure provides a robust margin of safety for any valuation recovery. The company reported profit attributable to shareholders of HKD 410 million in 2024. Equity attributable to owners of the company stood at HKD 9.421 billion at end-2024. The gearing ratio declined from 15.9% at end-2024 to 10.9% by Q3 2025. In respect of the 2024 financial year, the company declared final dividend and special dividend totalling HKD 888 million, and together with the interim dividend of HKD 208 million, full-year distributions reached HKD 1.096 billion — exceeding 200% of the year's attributable profit. This combination of strong dividend commitment, low financial leverage, and sustained earnings power positions the stock favourably for capital flows seeking both "growth" and "income" attributes simultaneously.Taken as a whole, the formal advancement of the Unitree Robotics IPO process represents one of the most consequential capital-markets events of 2026 for the embodied-intelligence industry. It not only raises the capital-markets certainty for leading robotics companies, but also opens a valuation re-rating window for ecosystem-type platforms like Shoucheng Holdings Limited. As the logic of "flagship project listing → investment return realisation → industrial scenario expansion → platform valuation uplift" progressively unfolds, Shoucheng Holdings is well-positioned to emerge as one of the core beneficiaries of this robotics market cycle — a company that simultaneously offers a meaningful margin of safety and meaningful upside optionality. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Singapore and Taipei, Mar 23, 2026 - (ACN Newswire via SeaPRwire.com) - AEM Holdings Ltd. (“AEM” or “the Group”), a global leader in test innovation, announced a strategic partnership with ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX) (“ASE”), the leading provider of semiconductor assembly, testing and materials (“ATM”) services and the provider of electronic manufacturing (“EMS”) services. The collaboration brings together AEM’s proprietary test technologies with ASE’s world-class manufacturing scale to deliver disruptive test solutions tailored for the rapidly expanding Artificial Intelligence (“AI”) and High-Performance Computing (“HPC”) markets.Aligned with the strategic partnership, AEM will raise approximately S$12 million in gross proceeds through a private placement of 3,350,000 million ordinary shares to a wholly owned subsidiary of ASE, representing 1.06% of AEM’s issued share capital as at 21 March 2026, at an issue price of S$3.591 per share. ASE, through said subsidiary, will also receive a total of 28,111,856 million free detachable warrants, divided equally into two exercisable tranches, with each tranche subject to certain ASE-attributable revenue-related conditions. Each warrant is exercisable into one ordinary share, with the Tranche 1 exercise price set at 103% of the volume weighted average price (“VWAP”) of AEM’s shares for the full market day on which the subscription agreement is signed, and the Tranche 2 exercise price set at 105% ofsuch VWAP. If fully exercised, the warrants would result in an additional 8.935% of the current issued share capital. The transaction remains subject to certain conditions, including the approval of the Singapore Exchange for the listing and quotation of the new shares.Proceeds from the private placement will support AEM’s continued expansion in Taiwan and the joint integration of AEM’s test technologies, including highly parallel test architectures and advanced thermal management capabilities, into ASE’s manufacturing and test environments. The funds will also be used to advance AEM’s product roadmap, enhance its system offerings, and accelerate joint go to market initiatives aimed at supporting next generation AI and HPC applications.The strategic partnership also supports ISE Labs, a wholly owned subsidiary of ASE, as it expands AI and HPC processor development capabilities to address early-stage testing, validation, and characterization requirements. These efforts focus on heterogeneous integration architectures, including multi-chiplet and advanced system-in-package designs as well as optical interconnect technologies critical to next-generation compute platforms. ASE’s ATM portfolio further strengthens these initiatives with high-volume advanced packaging and test capabilities, enabling production-scale deployment as global demand continues to accelerate.Ken Hsiang, Chief Executive Officer of ISE Labs, stated: “As compute architectures grow more complex and time-to-production continues to compress, test has become a critical enabler of performance, reliability, and manufacturability for next-generation AI and HPC systems. By combining ISE’s advanced characterization and production-readiness capabilities with AEM’s scalable, high-parallel test technologies and system-level engineering strengths, this strategic partnership enables rapid transition from validation to ASE’s high-volume deployment while addressing the increasing complexity of advanced compute testing.”Samer Kabbani, Chief Executive Officer of AEM, commented, “This partnership represents an important step in AEM’s strategy to work closely with industry leaders to advance the state of AI and HPC testing. ASE’s forward-looking approach and global scale make them an ideal partner as test requirements continue to intensify across advanced compute platforms. By combining our respective strengths, we aim to develop and deploy next-generation test solutions that help customers improve performance, scalability, and time-to-market.”About ASE Technology Holding Co., Ltd.ASEH is the leading provider of semiconductor manufacturing services in assembly and test. The Company develops and offers complete turnkey solutions covering front-end engineering test, wafer probing and final test, as well as packaging, materials and electronic manufacturing services through USI with superior technologies, breakthrough innovations, and advanced development programs. With advanced technological capabilities and a global presence spanning Taiwan, China, South Korea, Japan, Singapore, Malaysia, Philippines, Vietnam, Mexico, and Tunisia as well as the United States and Europe, ASEH has established a reputation for reliable, high quality products and services. For more information, please visit our website at https://www.aseglobal.com.About AEMAEM is a global leader in test innovation. We provide the most comprehensive semiconductor and electronics test solutions based on the best-in-class technologies, processes, and customer support. AEM has a global presence across Asia, Europe, and the United States. AEM's R&D centres are situated in Singapore, Malaysia, Finland, France, and the US. With manufacturing plants located in Singapore, Malaysia (Penang), Indonesia (Batam), Vietnam, Finland (Lieto), South Korea, and the United States and a global network of engineering support, sales offices, associates, and distributors, we offer our customers a robust and resilient ecosystem of test innovation and support.AEM Holdings Ltd. is listed on the main board of the Singapore Exchange (Reuters: AEM. SI; Bloomberg: AEM SP). AEM’s head office is in Singapore.For more information please contact:Kamal SAMUEL / Rishika TIWARI / LIM En Tong Financial PR Pte LtdTel: 6438 2990 / Fax: 6438 0064E-mail: kamal@financialpr.com.sg / rishika@financialpr.com.sg / entong@financialpr.com.sgPatricia MacLeod ASE, Inc.Tel: +1 408 314 9740E-mail: patricia.macleod@aseus.com Safe Harbor Notice (ASE)This press release contains "forward-looking statements" within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although these forward-looking statements, which may include statements regarding our future results of operations, financial condition or business prospects, are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to us, are intended to identify these forward-looking statements in this press release. These forward-looking statements are necessarily estimates reflecting the best judgment of our senior management and our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied by the forward-looking statements for reasons including, among others, risks associated with cyclicality and market conditions in the semiconductor or electronic industry; changes in our regulatory environment, including our ability to comply with new or stricter environmental regulations and to resolve environmental liabilities; demand for the outsourced semiconductor packaging, testing and electronic manufacturing services we offer and for such outsourced services generally; the highly competitive semiconductor or manufacturing industry we are involved in; our ability to introduce new technologies in order to remain competitive; international business activities; our business strategy; our future expansion plans and capital expenditures; the strained relationship between the Republic of China and the People’s Republic of China; general economic and political conditions; the recent shift in United States trade policies; possible disruptions in commercial activities caused by natural or human-induced disasters; fluctuations in foreign currency exchange rates; and other factors. The announced results of the full year of 2025 are preliminary and subject to audit adjustments. For a discussion of these risks and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including the 2024 Annual Report on Form 20-F filed on March 27, 2025.Disclaimer (AEM)This is a press release of general information relating to the current activities of AEM Holdings Ltd. (“AEM”). It is given in summary form and does not purport to be complete. This press release may contain forward-looking statements which are subject to risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in these forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other companies, shifts in customer demands, customers and partners, changes in operating expenses, governmental and public policy changes, and the continued availability of financing. Accordingly, such statements are not and should not be construed as a representation as to the future of AEM, and are not intended to be profit forecasts, estimations or projections of future performance and should not be regarded as such. No reliance should therefore be placed on these forward-looking statements, which are based on the current views of the management of AEM. The press release is also not to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. AEM accepts no responsibility whatsoever with respect to the use of this document or any part thereof. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年3月20日 - (亚太商讯 via SeaPRwire.com) - 北京同仁堂医养投资股份有限公司（以下简称"同仁堂医养"）在资本市场的聚光灯下宣布进行全球发售，中金公司担任独家保荐人，将于3月30日开始挂牌交易。根据公告内容，本次全球发售的H股总数为108,153,500股。其中，香港公开发售股分为10,815,500股，国际发售股分为97,338,000股，两者均可予重新分配。此次冲刺意味着这个中药老字号正通过资本纽带，将自身沉淀了三百多年的品牌理念和中医医养延伸进更多场景和地区。走向港股市场后，同仁堂集团将补齐"制药-零售-医养"大健康生态圈的最后一块拼图。在万亿级中医医疗服务赛道中，这个357年的金字招牌究竟值多少？厚积薄发：中医医疗服务的领跑者同仁堂作为中国为数不多的拥有三百多年品牌历史的民族企业，这块金字招牌自2019年开始大步进军中医医疗服务赛道，致力于将传统中医药精髓与现代医疗管理服务相结合。作为同仁堂集团唯一战略性聚焦于中医医疗服务的子公司，同仁堂医养结合"医疗"与"养生"，通过标准化的连锁经营以及现代化的管理系统，提供一站式定制化中医医疗服务，综合覆盖全场景中医诊疗需求，成为便捷可及的中医健康专家。招股书显示，同仁堂医养的门诊服务收入在中国非公立中医院医疗服务行业的所有中医集团中排名第一，是第二大医院集团的2倍；其门诊及住院人次在中国非公立中医院医疗服务行业的所有中医院集团中排名第一。按2024年总门诊人次及住院人次计，同仁堂医养是中国非公立中医院医疗服务行业中最大的中医院集团。该细分市场的规模已占同年中国中医医疗服务行业总市场规模的46.5%。在这个极度分散、缺乏龙头的中医医疗服务市场，能够拿下"头把交椅"，本身就是同仁堂医养百年品牌底蕴加持下厚积薄发的底气， 而1.7%的市占率也意味着龙头企业的整合空间才刚刚开始。四大投资逻辑：为什么此刻值得关注逻辑一：业绩已过验证期，增长质量持续提升据悉，公司FY22-FY24年收入CAGR（年复合增长率）高达13.6%，FY22-FY24年毛利CAGR高达24.8%，毛利增速远超营收增速，盈利结构持续优化，跑出了稀缺的增长质量。FY2024现金转化率为87.2%，拥有非常强健的内部流动性，"赚到的利润是真金白银"。期间费用率从17.1%降至13.6%，三年下降3.47个百分点，规模效应加速兑现。 有息债务占比仅11.56%，经营性现金流持续净流入，截至2025年9月现金2.25亿元，具有充分的安全垫，已经进入"增长和盈利"正相关的良性循环。逻辑二：全产业链协同的"降维打击"同仁堂医养依托的是百年积淀所形成的产业壁垒--同仁堂集团深入中医药行业全产业链，拥有深度的产业链协同能力。其自建的医疗服务网络覆盖医院、门诊部及诊所、社区医疗机构等，一旦与同仁堂遍布全国的药诊店相结合，其机构密度和服务能力将呈现指数级增长。据披露信息显示，其已经开始于自建的互联网医院为线下药房和医师提供线上医疗服务，目前业务范围覆盖全国。此外，依托同仁堂集团资源，公司通过收购三溪堂国药馆以及获得安宫牛黄丸系列产品在浙江区域的独家零售权后销量大增，公司健康产品和其他产品的销量在整个往绩记录期间实现爆发式增长。依托这块金字招牌，公司的推广费用率仅0.2%，远低于行业平均水平--别人花大价钱获客，同仁堂天然自带流量。正如市场分析人士指出，同仁堂的资本棋局，本质是通过专业化分拆实现精准发力。医养板块作为"最后一公里"，不仅直接创造营收，更成为拉动同仁堂集团中药产品销售、增强用户粘性的超级入口。同仁堂医养上市后，同仁堂的"制药-零售-医养"三位一体的大健康生态圈将完整闭合。逻辑三：内生外延双轮驱动，增长飞轮已形成如果说品牌和集团资源是"先天优势"，那么同仁堂医养通过"内生+外延"构建起的服务网络，则是其征战资本市场的"后天壁垒"。同仁堂医养已建立了一个分层级、广覆盖的中医医疗服务网络。据招股书显示，公司拥有15家医院，覆盖北京市、浙江省、山西省、辽宁省、黑龙江省、贵州省、新疆维吾尔自治区；9家基层医疗机构，覆盖北京市、浙江省、上海市，及1家互联网医院，形成了"线下首诊+线上复诊"的业务闭环。在扩张路径上，公司采取"并购+自建+管理"多轮驱动模式。为了快速切入长三角经济发达地区，公司相继收购了浙江三溪堂、上海承志堂等当地知名机构，通过"品牌赋能+标准化管理"实现收购标的的快速整合与业绩提升。根据信息，其以轻资产方式自建的方式在齐齐哈尔、北京顺义等地的新机构即将开业，同时通过向非营利性医疗机构输出管理经验、医师和人才、标准化的服务，同仁堂医养正将"同仁堂标准"复制到更广阔的市场。逻辑四：守正创新，AI+中医打开想象空间中医药老字号的焕新，既要守住"正"，也要创造"新"。这一点，这一点在同仁堂系的各个板块均有体现。2025年8月25日，公开报道显示，同仁堂股份与小米商业营销达成合作，推出"同仁堂养生馆"AI智能中医药健康服务智能体，将中医药知识与AI交互能力结合，面向用户提供个性化的养生建议、用药指导与节气调养方案，已经形成"咨询-建议-服务-购药"闭环。可见，通过引入AI智能问诊与健康检测设备，同仁堂正在推动自身从"被动卖药"向"主动健康管理"转型，让百年药铺变身便民的"智慧健康服务站" 。作为同仁堂集团大健康版图的关键一块，同仁堂医养不仅承载着老字号在医疗服务领域的创新探索，更以其清晰的分级诊疗布局、深厚的医师资源及强大的产业协同效应，向资本市场讲述了一个关于传承与创新的长期主义叙事。此次赴港IPO，对于同仁堂医养而言，既是机遇也是挑战。作为拥有三百五十余年历史的中医药老字号，同仁堂不仅即将打通"中医药全产业链"的资本闭环，更将为老字号在AI经济浪潮中探索出一条"智能中医"的新路径。百年金字招牌如何通过资本的力量再次焕发光彩，市场正拭目以待。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Mar 20, 2026 - (ACN Newswire via SeaPRwire.com) – The 30th Hong Kong International Film & TV Market (FILMART) and EntertainmentPulse, organised by the Hong Kong Trade Development Council (HKTDC), concluded successfully today. The two events attracted about 8,000 industry professionals from 53 countries and regions, highlighting the development momentum and collaborative potential of the global film and television industry. The events, held over four days, featured over 790 exhibitors across a record high participation of 38 countries and regions, bringing together enterprises from emerging markets like ASEAN members such as Cambodia, Malaysia, Thailand, and Vietnam, and mature film markets such as Canada, France, Italy, Korea, the United Kingdom, and the United States, further exemplifying Hong Kong’s position as a centre for cultural and artistic exchange.FILMART advances international collaboration in the film and television industryThis year’s FILMART continued to demonstrate its role as one of the region’s most influential film and television trading platforms, bringing together exhibitors, buyers and producers from both emerging and mature markets to facilitate cross-regional collaboration and business cooperations. Participating in FILMART for the first time, the General Manager of COL International Group, Timothy Oh from Singapore, noted that FILMART plays a key role in helping companies expand their international networks, he said: "I am meeting friends and new business partners from Turkey, the UK, the US, and even Brazil. Hong Kong’s role as an international hub helps create a bustling market with many business opportunities for those looking at innovation and what’s next.” Sachitha Kalingamudali, General Manager of another first-time exhibitor Mogo Studios from Sri Lanka, said FILMART exceeded his expectations. "We've met distributors from many countries, and everyone has shown genuine interest. This is a great kickstart for future partnerships." Myanmar film production company aTwentyThree even chose FILMART as its first move to explore the international market, founder Arker Soe Oo connected with distributors from the US and Europe, and expressed plans to bring more productions to the event next year.Overseas buyers also expressed strong recognition of the exhibition’s business matching effectiveness and the diversity of its content, further affirming that FILMART serves as an efficient platform for advancing collaboration across the global film and television value chain and strengthening market connectivity. Bizhan Tong, a buyer from the UK, commented: “FILMART continues to be one of the most effective platforms globally for driving cross-border collaboration. This year we formed a new strategic partnership with MOFAC, advanced multiple projects across both our and other companies' slates, and saw a highly concentrated run of meetings with partners across Asia translating into tangible co-investment and co-production opportunities.”AI Hub supports Mainland tech companies in going globalA highlight of this year’s FILMART was AI Hub which had multiple leading AI and technology companies showcasing their latest AI technologies and solutions, attracting buyers and potential partners from around the world for business discussions and exchanges. Through this platform, many Mainland start-ups and established enterprises have accelerated their expansion into overseas markets and built international networks, further enhancing brand visibility and converting opportunities into concrete business outcomes. Zhihan Zhang, Founder and CEO of Daogu Culture Limited, remarked, “Whether it is AI animation, short dramas, or digital humans, the key to the future lies in global strategy. FILMART gathers global industry professionals, facilities connections and exchanges, and enables us to understand the various client needs of different overseas markets.” In addition, the newly established "AI Academy", supported by the Cultural and Creative Industries Development Agency and the Film Development Fund, was well-received. 19 thematic workshops equipped industry professionals with hands-on AI skills and insights into emerging trends.Producers Connect fosters collaboration between local and global producersProducers Connect, jointly organised by the HKSAR’s Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the Hong Kong Film Development Council and the HKTDC, united more than 100 producers from Hong Kong and around the world this year. Through a series of networking sessions, panel discussions and workshops, Producers Connect provided a cross-regional platform for creative collaboration, enabling industry professionals to share production trends, explore co-production models and discuss potential projects. The initiative strengthens connections between Hong Kong and the international film and television community, creating more possibilities for jointly expanding into the global market. Speaking at the panel discussion titled “International Coproductions in an Evolving Film Industry Landscape,” Janet Yang, Golden Globe-winning producer, observed: “The world is getting flatter, language is mattering less and less to audiences everywhere.” Producer and director Peter Chan also mentioned: “It’s always difficult to convince the studio, the investor, or now the platform, of a vision you want to make. What you try to do is diversify your investors and partners into different regions.”48 featured forums and events examine emerging industry trendsTwo major forums held alongside FILMART — EntertainmentPulse and the Digital Entertainment Summit — focused on the latest developments in the global film, television and entertainment technology sectors, attracting strong participation from industry professionals. EntertainmentPulse addressed popular topics including artificial intelligence, streaming platform strategies, the rising popularity of short dramas, co-production and financing trends. Industry leaders shared insights on global market strategies and future directions, helping the sector capture emerging opportunities. The Financing & Investment panel, themed “Capital in Motion: Private Financing Promotes Development of Asia’s Film & TV Industry,” explored Asian private investment trends, project financing strategies and planning. Justin Deimen, Managing Partner of Goldfinch International, shared: “We need to allocate more resources and capability towards creative IP valuation. If you cannot value something, you cannot invest in it.”Meanwhile, FILMART Online IP Catalogue featured more than 2,200 creative IP projects, extending the four-day physical fair into a two-month networking platform helping industry stakeholders continue exploring business opportunities. This initiative further consolidated Hong Kong’s position as Asia’s film and entertainment trading hub. The catalogue will remain open until 27 April, enabling industry participants to transcend geographical boundaries and continue expanding global business opportunities.Website:FILMART— http://www.hktdc.com/hkfilmartEntertainmentPulse—https://hkfilmart.hktdc.com/conference/hkfilmart/en/programme'category=EntertainmentPulsePhoto Download: https://bit.ly/4sxPP6I The 30th Hong Kong International Film & TV Market (FILMART) and the EntertainmentPulse, organised by the Hong Kong Trade Development Council (HKTDC), concluded successfully today. The two events attracted about 8,000 industry professionals from 53 countries and regions, highlighting the development momentum and collaborative potential of the global film and television industryThis year, FILMART welcomes the first-time participation of emerging markets including Belgium, Poland, Sri Lanka, Myanmar, and Uzbekistan; the picture shows the exhibitor from UzbekistanThe AI Hub displays the latest AI technologies and solutions, assisting Mainland tech companies take a crucial step in going globalProducers Connect’s panel discussion specially invited renowned director Peter Chan (second left) and Golden Globe Award-winning producer Janet Yang (second right) to attend, bringing new inspirations and directions for international co-productions to the industryEntertainmentPulse addresses a range of popular topics, including artificial intelligence, streaming platform strategies, the rising popularity of short dramas, co-production and financing trends. Industry leaders share insights on global market strategies and future directions, helping the sector capture emerging opportunitiesMedia enquiries:For enquiries, please contact:Raconteur PR:Betsy TseTel: (852) 9742 7338 Email: betsytse@raconteur.hkMolisa LauTel: (852) 6187 7786 Email: molisalau@raconteur.hkHKTDC Communication and Public Affairs Department:Serena Cheung Tel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgHKTDC Mediaroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TOKYO, Mar 20, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) announces that its Board of Directors tentatively decided, at a meeting held on February 16, 2026, the appointment of new Audit & Supervisory Board Members. The Boards of Directors of each group company—TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd., TANAKA PRECIOUS METAL RETAILING Co., Ltd., and TANAKA ELECTRONICS Co., Ltd.—also tentatively decided on the same appointment.Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/ TANAKA’s Executive Appointments1. TANAKA PRECIOUS METAL GROUP Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.2. TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed Audit & Supervisory Board MemberHiroyuki SakamotoNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.3. TANAKA PRECIOUS METAL RETAILING Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.4. TANAKA ELECTRONICS Co., Ltd. (Effective of March 26, 2026)New PositionName Previous PositionAudit & Supervisory Board MemberNobutaka AokiNewly Appointed *The Audit & Supervisory Board Member is scheduled to be appointed at the Annual General Meeting of Shareholders to be held on March 26, 2026.*Satoru Ochiai is scheduled to retire from the position of Audit & Supervisory Board Member effective March 26, 2026.Press Release: https://www.acnnewswire.com/docs/files/20260320.pdf Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
